Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has earned an average recommendation of “Hold” from the eight brokerages that are currently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $25.50.
LXRX has been the topic of a number of analyst reports. Zacks Investment Research upgraded shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, August 3rd. BidaskClub cut shares of Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Thursday, October 4th. Needham & Company LLC reiterated a “hold” rating on shares of Lexicon Pharmaceuticals in a research note on Monday, June 25th. ValuEngine upgraded shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, August 28th. Finally, Wedbush reiterated a “buy” rating and issued a $42.00 price target on shares of Lexicon Pharmaceuticals in a research note on Monday, June 18th.
A number of large investors have recently modified their holdings of LXRX. BlackRock Inc. raised its position in Lexicon Pharmaceuticals by 4.6% in the 2nd quarter. BlackRock Inc. now owns 4,422,293 shares of the biopharmaceutical company’s stock worth $53,066,000 after buying an additional 195,461 shares during the last quarter. Price Capital Management Inc. purchased a new position in Lexicon Pharmaceuticals in the 2nd quarter worth about $1,352,000. Bank of Montreal Can raised its position in Lexicon Pharmaceuticals by 8,364.1% in the 3rd quarter. Bank of Montreal Can now owns 122,053 shares of the biopharmaceutical company’s stock worth $1,302,000 after buying an additional 120,611 shares during the last quarter. UBS Group AG raised its position in Lexicon Pharmaceuticals by 94.5% in the 1st quarter. UBS Group AG now owns 218,923 shares of the biopharmaceutical company’s stock worth $1,876,000 after buying an additional 106,392 shares during the last quarter. Finally, A.R.T. Advisors LLC raised its position in Lexicon Pharmaceuticals by 71.0% in the 1st quarter. A.R.T. Advisors LLC now owns 54,266 shares of the biopharmaceutical company’s stock worth $465,000 after buying an additional 22,533 shares during the last quarter.
Shares of LXRX stock traded up $0.15 during mid-day trading on Wednesday, reaching $8.77. 348,564 shares of the company’s stock traded hands, compared to its average volume of 566,070. Lexicon Pharmaceuticals has a 12 month low of $7.67 and a 12 month high of $13.97. The stock has a market cap of $1.13 billion, a PE ratio of -6.91 and a beta of 0.35. The company has a current ratio of 2.71, a quick ratio of 2.68 and a debt-to-equity ratio of -45.80.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its earnings results on Monday, July 30th. The biopharmaceutical company reported ($0.33) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.35) by $0.02. The firm had revenue of $13.75 million for the quarter, compared to analysts’ expectations of $15.88 million. Lexicon Pharmaceuticals had a negative net margin of 137.32% and a negative return on equity of 369.13%. The company’s quarterly revenue was up 14.1% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.33) EPS. On average, sell-side analysts forecast that Lexicon Pharmaceuticals will post -1.38 earnings per share for the current fiscal year.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Recommended Story: Stock Symbols and CUSIP Explained
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.